Keros Therapeutics, Inc. — insider transactions

3 transactions on record · KROS · CIK 1664710

Aggregates

computed from the filings below
Purchases, 12m
2
count of open-market buys
Sales, 12m
1
count of open-market sales
Buy / sell ratio, 12m
2.00
purchases per sale
Distinct insiders, 12m
2
Bought, 3m
$20.9K
Sold, 3m
$46.2K
Median disclosure lag
2.0 d
trade date to filing date
Largest single trade, 24m
$46.2K
2026-08-18
Director share, 12m
66.7%
of transactions where role is stated
Current run
1 sells
consecutive same-direction transactions
Net 3m flow
-$25.3K
purchases minus sales
Total on record
3

Transactions

3 most recent shown
DisclosedTradedLag, dInsiderRoleTransactionSharesPriceValueSource
2026-08-202026-08-182Cho EstherChief Legal OfficerOpen market sale4,485$10.29$46.2Kfiling
2026-08-192026-08-172BIENAIME JEAN JACQUESDirectorOpen market purchase1,000$10.27$10.3Kfiling
2026-07-172026-07-152BIENAIME JEAN JACQUESDirectorOpen market purchase1,000$10.61$10.6Kfiling

Source: U.S. Securities and Exchange Commission, EDGAR

Keros Therapeutics, Inc. insider transactions — 3 filings on record — investment.com